FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease, also called metabolic dysfunction‐associated steatotic liver disease, is the most common liver disease worldwide and has no approved pharmacotherapy. Due to its beneficial effects on metabolic regulation, inflammation suppression, cell death prevention, and fibrogenesis inhibition, farnesoid X receptor (FXR) is widely accepted as a promising therapeutic target for nonalcoholic steatosis (NASH) or called metabolic dysfunction‐associated steatohepatitis (MASH). Many FXR agonists have been developed for NASH/MASH therapy. Obeticholic acid (OCA) is the pioneering frontrunner FXR agonist and the first demonstrating success in clinical trials. Unfortunately, OCA did not receive regulatory approval as a NASH pharmacotherapy because its moderate benefits did not outweigh its safety risks, which may cast a shadow over FXR‐based drug development for NASH/MASH. This review summarizes the milestones in the development of OCA for NASH/MASH and discuss its limitations, including moderate hepatoprotection and the undesirable side effects of dyslipidemia, pruritus, cholelithiasis, and liver toxicity risk, in depth. More importantly, we provide perspectives on FXR‐based therapy for NASH/MASH, hoping to support a successful bench‐to‐clinic transition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636 · cited 1×
“49 Since CDCA was identified as the most potent endogenous ligand for FXR, it was used as a skeleton in the development of synthetic BA analogs as potent FXR agonists.”
BackgroundSelf-citationBile acid metabolites control TH17 and Treg cell differentiation
Hang, S., Paik, D., Yao, L., Kim, E., Trinath, J., Lu, J., Ha, S., Nelson, B. N., Kelly, S. P., Wu, L., et al. (2019) · Nature · doi:10.1038/s41586-019-1785-z · Cited by 1,457
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Vitamin D Receptor As an Intestinal Bile Acid Sensor
Makishima, M., Lu, T. T., Xie, W., Whitfield, G. K., Domoto, H., Evans, R. M., Haussler, M. R., & Mangelsdorf, D. J. (2002) · Science · doi:10.1126/science.1070477 · Cited by 1,176
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · cited 1×
“66 On the basis of above results, investigators further evaluated its efficacy in nondiabetic NASH patients.”
BackgroundA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101133 · Cited by 844
Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
Fuchs, C. D., & Trauner, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00566-7 · Cited by 490
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Kabashima, K., Matsumura, T., Komazaki, H., & Kawashima, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917006 · Cited by 361
Loomba, R., Kayali, Z., Noureddin, M., Ruane, P., Lawitz, E. J., Bennett, M., Wang, L., Harting, E., Tarrant, J. M., McColgan, B. J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.027 · Cited by 340 · cited 1×
“97 The effect of combined cilofexor and firsocostat 44 agonist.”
BackgroundLoomba, R., Noureddin, M., Kowdley, K. V., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N., Caldwell, S. H., Goodman, Z., et al. (2021) · Hepatology · doi:10.1002/hep.31622 · Cited by 296 · cited 1×
“97 The effect of combined cilofexor and firsocostat 44 agonist.”
BackgroundAlkhouri, N., Herring, R., Kabler, H., Kayali, Z., Hassanein, T., Kohli, A., Huss, R. S., Zhu, Y., Billin, A. N., Damgaard, L. H., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.003 · Cited by 230 · cited 1×
“98 The effect of combined cilofexor 99 and semaglutide, another GLP ‐ 1R agonist, is under evaluation in a phase II trial.”
BackgroundFiorucci, S., Rizzo, G., Antonelli, E., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pruzanski, M., Morelli, A., & Pellicciari, R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084905 · Cited by 183
Rinella, M. E., Dufour, J.-F., Anstee, Q. M., Goodman, Z., Younossi, Z., Harrison, S. A., Loomba, R., Sanyal, A. J., Bonacci, M., Trylesinski, A., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.029 · Cited by 164 · cited 1×
“69 The Study Evaluating the Efficacy and Safety of OCA in Subjects with Compensated Cirrhosis due to NASH (REVERSE) is another multicenter, double ‐ blind, randomized, placebo ‐ controlled phase III trial in patients with NASH ‐ related compensated cirrhosis (NCT03439254).”
BackgroundSUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
Zhou, J., Cui, S., He, Q., Guo, Y., Pan, X., Zhang, P., Huang, N., Ge, C., Wang, G., Gonzalez, F. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14138-6 · Cited by 154 · cited 3×
“13,14 Thus, this NR is extensively accepted as one of the most promising targets for drug development for MASLD.”
BackgroundSelf-citationEDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study
Ratziu, V., Rinella, M. E., Neuschwander-Tetri, B. A., Lawitz, E., Denham, D., Kayali, Z., Sheikh, A., Kowdley, K. V., Desta, T., Elkhashab, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.018 · Cited by 123
Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
Zhou, J., Huang, N., Guo, Y., Cui, S., Ge, C., He, Q., Pan, X., Wang, G., Wang, H., & Hao, H. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.004 · Cited by 99
Self-citationNonsteroidal FXR Ligands: Current Status and Clinical Applications
Gege, C., Hambruch, E., Hambruch, N., Kinzel, O., & Kremoser, C. (2019) · Handbook of Experimental Pharmacology · doi:10.1007/164_2019_232 · Cited by 83
Jouihan, H., Will, S., Guionaud, S., Boland, M. L., Oldham, S., Ravn, P., Celeste, A., & Trevaskis, J. L. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.001 · Cited by 59
Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis
Wang, H., Ge, C., Zhou, J., Guo, Y., Cui, S., Huang, N., Yan, T., Cao, L., Che, Y., Zheng, Q., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.10.028 · Cited by 55
Self-citation
Cited by
Azizsoltani, A., Niknam, B., Taghizadeh-Teymorloei, M., Ghoodjani, E., Dianat-Moghadam, H., & Alizadeh, E. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118249 · Cited by 15
Constructing biomimetic microenvironments for liver regeneration
(2025) · doi:10.1186/s12951-025-03729-9 · Cited by 11
Yanagisawa, H., Maeda, H., Noguchi, I., Tanaka, M., Wada, N., Nagasaki, T., Kobayashi, K., Kanazawa, G., Taguchi, K., Chuang, V. T. G., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103314 · Cited by 10
“…trials of various drugs such as Toll-like receptor 4 (TLR4) inhibitors [5], dual peroxisome proliferator activated receptor (PPAR)- α /PPAR-γ agonists [6], farnesoid X receptor agonists [7,8], acetyl CoA carboxylase inhibitors [9], and CCR2/5 inhibitors [10,11] are currently underway or completed.”
Background
Metadata
- Authors
- Wang, K., Zhang, Y., Wang, G., Hao, H., & Wang, H.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2023-10-30
- Volume
- 44
- Issue
- 2
- Pages
- 568-586
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W4388013971
- Cited by
- 117
- References
- 25
- FWCI
- 19.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.